Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Orhan Sezer

Showing results (11-20 of 109) with videos related to

Pageof 11
Sort By:
British Journal of Haematology|April 30, 2003
Circulating hepatocyte growth factor levels in multiple myelomaChristian Jakob, Claudia Fleissner, Ivana Zavrski, et al.
European Journal of Haematology|August 22, 2003
Bisphosphonates in early multiple myelomaOrhan Sezer, Christian Jakob, Ivana Zavrski, et al.
Blood|November 9, 2002
RANK ligand and osteoprotegerin in myeloma bone diseaseOrhan Sezer, Ulrike Heider, Ivana Zavrski, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|July 5, 2007
Molecular and clinical aspects of proteasome inhibition in the treatment of cancerIvana Zavrski, Christian Jakob, Martin Kaiser, et al.
British Journal of Haematology|June 27, 2007
Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPKMonica Hecht, Ulrike Heider, Martin Kaiser, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 8, 2010
Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomibUlrike Heider, Jessica Rademacher, Martin Kaiser, et al.
Biochemical and Biophysical Research Communications|October 12, 2005
Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone diseaseUlrike Heider, Lorenz C Hofbauer, Ivana Zavrski, et al.
Pharmacogenetics|April 30, 2004
Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonistsRolf Kaiser, Pierre-Benoit Tremblay, Orhan Sezer, et al.
Biochemical and Biophysical Research Communications|June 7, 2005
Proteasome inhibitors abrogate osteoclast differentiation and osteoclast functionIvana Zavrski, Holger Krebbel, Britt Wildemann, et al.
European Journal of Cancer (Oxford, England : 1990)|June 13, 2006
Bone markers in multiple myelomaUlrike Heider, Claudia Fleissner, Ivana Zavrski, et al.
Pageof 11

Showing results (11-20 of 109) with videos related to

Sort By:
Pageof 11
British Journal of Haematology|April 30, 2003
Circulating hepatocyte growth factor levels in multiple myelomaChristian Jakob, Claudia Fleissner, Ivana Zavrski, et al.
European Journal of Haematology|August 22, 2003
Bisphosphonates in early multiple myelomaOrhan Sezer, Christian Jakob, Ivana Zavrski, et al.
Blood|November 9, 2002
RANK ligand and osteoprotegerin in myeloma bone diseaseOrhan Sezer, Ulrike Heider, Ivana Zavrski, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|July 5, 2007
Molecular and clinical aspects of proteasome inhibition in the treatment of cancerIvana Zavrski, Christian Jakob, Martin Kaiser, et al.
British Journal of Haematology|June 27, 2007
Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPKMonica Hecht, Ulrike Heider, Martin Kaiser, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 8, 2010
Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomibUlrike Heider, Jessica Rademacher, Martin Kaiser, et al.
Biochemical and Biophysical Research Communications|October 12, 2005
Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone diseaseUlrike Heider, Lorenz C Hofbauer, Ivana Zavrski, et al.
Pharmacogenetics|April 30, 2004
Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonistsRolf Kaiser, Pierre-Benoit Tremblay, Orhan Sezer, et al.
Biochemical and Biophysical Research Communications|June 7, 2005
Proteasome inhibitors abrogate osteoclast differentiation and osteoclast functionIvana Zavrski, Holger Krebbel, Britt Wildemann, et al.
European Journal of Cancer (Oxford, England : 1990)|June 13, 2006
Bone markers in multiple myelomaUlrike Heider, Claudia Fleissner, Ivana Zavrski, et al.
Pageof 11